Advertisement

FDA Approves Novel Implanted Sensor to Monitor Heart Failure — Physician’s First Watch

Medical News |
May 29, 2014

FDA Approves Novel Implanted Sensor to Monitor Heart Failure

By Larry Husten

Edited by Susan Sadoughi, MD , and Lorenzo Di Francesco, MD, FACP, FHM

The FDA has approved the CardioMEMS HF System — a small implantable device that provides daily pulmonary artery (PA) pressure measurements to guide physicians in their treatment of patients who have been hospitalized with heart failure (New York Heart Association Class III) in the previous year.

The system consists of three parts: a small permanent sensor implanted in the pulmonary artery, a catheter-based delivery system, and a system that acquires and processes PA pressure measurements from the implanted monitor and transfers the data to a secure database.

In a news release, the FDA said that it "believes that there is reasonable assurance that the device is safe and effective for heart failure management with the goal of reducing the rate of heart failure–related hospitalizations in certain patients." The agency is requiring the company to conduct a postapproval study to examine how the device performs outside clinical trials.

Adapted from CardioExchange

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement